Jubilant Pharmova Ltd

Jubilant Pharmova Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 21 July 2026. The stock’s recent price action and technical indicators signal a bearish trend, reflecting growing investor caution amid broader market pressures and sector-specific challenges.

Jubilant Pharmova Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 02 August 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Jubilant Pharmova Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 21 July 2026. This change reflects a combination of deteriorating technical indicators, flat financial performance, and subdued long-term growth prospects, despite an attractive valuation relative to peers.

Jubilant Pharmova Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical parameters, moving from a mildly bullish to a mildly bearish trend. This change accompanies a 2.78% decline in its share price to ₹995.45 on 22 Jul 2026, reflecting growing investor caution despite the company’s strong long-term returns relative to the Sensex.

Jubilant Pharmova Ltd has seen its investment rating upgraded from Sell to Hold as of 16 July 2026, reflecting a nuanced improvement across technical indicators and valuation metrics despite ongoing challenges in financial performance and market returns. This reassessment by MarketsMOJO highlights a shift in the company’s technical trend to mildly bullish, alongside an attractive valuation relative to peers, balanced against flat quarterly results and subdued long-term growth.

Jubilant Pharmova Ltd has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. Despite a slight dip in the daily price, key indicators such as MACD and Bollinger Bands on weekly and monthly charts suggest improving momentum, while mixed signals from RSI and moving averages warrant cautious optimism among investors.

Jubilant Pharmova Ltd has experienced a notable shift in its price momentum, reflected in a complex interplay of technical indicators that suggest a transition from a mildly bearish trend to a sideways consolidation phase. Despite a strong day change of 5.49%, the stock’s technical landscape presents a nuanced picture, with bullish signals on some weekly and monthly indicators contrasting with bearish cues on others, underscoring the need for cautious analysis by investors.

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Jubilant Pharmova Ltd is rated Sell by MarketsMOJO, with this rating last updated on 10 April 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 19 June 2026, providing investors with an up-to-date analysis of the company’s standing in the market.

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 April 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Jubilant Pharmova Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, posted a flat financial performance for the quarter ended March 2026, signalling a stabilisation after a period of decline. While net sales reached a record high, profitability metrics showed contraction, reflecting margin pressures and operational challenges. The company’s recent financial trend has improved from negative to flat, yet the overall outlook remains cautious with a Sell mojo grade.

Jubilant Pharmova Ltd., a mid-sized pharmaceutical company with a market capitalisation of ₹16,232 crores, reported a consolidated net profit of ₹119.40 crores for Q4 FY26, marking a dramatic 113.60% sequential jump from ₹55.90 crores in Q3 FY26. However, the year-on-year comparison reveals a concerning 22.27% decline from ₹153.60 crores in Q4 FY25, highlighting the uneven nature of the company's profitability trajectory. The stock currently trades at ₹1,005.75, down 0.54% on the day of this analysis.